Connor, Clark & Lunn Investment Management Ltd.

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1596800 VANCOUVER, A1

Position in NTLA

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$9,597,513

+$7,262,730 QoQ

Shares Held

748,636

+188.3% QoQ

Ownership

0.536%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2021

8 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $703,286,486 across 100 Biotechnology names. NTLA ranks #16 (1.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	TERN	Terns Pharmaceuticals, Inc.	384,681	$20,280,382

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$9,597,513	748,636	+188.3%	Shares	Sole	2026-05-11
2025-12-31	$2,334,783	259,709	+62.0%	Shares	Sole	2026-02-10
2022-09-30	$8,973,521	160,356	+463.0%	Shares	Sole	2022-11-10
2022-06-30	$1,474,124	28,480	+170.3%	Shares	Sole	2022-08-05
2022-03-31	$765,723	10,537	-82.9%	Shares	Sole	2022-05-12
2021-09-30	$8,281,347	61,732	-6.6%	Shares	Sole	2021-11-12
2021-06-30	$10,704,193	66,112	+320.2%	Shares	Sole	2021-08-12
2021-03-31	$1,262,571	15,732	—	Shares	Sole	2021-05-13
No filing history on record for this holder in this stock.